[144] MiNK Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

MiNK Therapeutics (INKT) filed a Form 144 proposing the sale of 786,750 shares of common stock, with an aggregate market value of $12,572,265, to be sold approximately on 08/29/2025 on the INKT exchange. The filing states these shares were originally issued on 07/05/2017 in an original issuance from the issuer when it was a wholly owned subsidiary of Agenus Inc.; the shares were acquired in exchange for Agenus Inc.'s initial capital contribution. The filer reports no securities sold in the past three months and provides the standard representation that no undisclosed material adverse information is known.

Positive

• None.

Negative

• Planned large sale: Proposed sale of 786,750 shares with an aggregate market value of $12,572,265, which could increase share supply.
• Materiality of position: The filing shows 3,966,392 shares outstanding and the proposed sale represents a substantial portion of that base as reported in the form.

Insights

Securities Analyst

TL;DR: A significant proposed insider sale is disclosed—786,750 shares worth $12.6M slated for late August 2025.

The notice documents a sizeable planned sale relative to the reported shares outstanding, indicating potential near-term increase in share supply. The filing confirms the shares trace to an original issuance tied to Agenus Inc.'s initial capital contribution in 2017. No recent sales in the prior three months are reported, and the filer attests to the absence of undisclosed material adverse information. This is a regulatory disclosure of intent to sell, not a completed transaction; market impact will depend on whether the sale executes and market absorption.

Corporate Governance Expert

TL;DR: Routine Rule 144 notice that notifies the market of proposed disposition by a related party from an original issuance.

The document provides provenance for the shares (original issuance, 07/05/2017) and includes the required attestation regarding material non-public information. The absence of disclosed trading plans or prior three-month sales suggests this is a first public notice of intent. As a Form 144, it maintains compliance transparency rather than signaling corporate action; governance implications center on insider liquidity rather than changes to company control or policy.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	B. Riley Financial 11000 Santa Monica Blvd, Suite 800, Los Angeles, CA 90025	786750	12572265.00	3966392	08/29/2025	INKT

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/05/2017	These shares were acquired in an original issuance from the issuer, which was incorporated as a wholly owned subsidiary of Agenus Inc.	MiNK Therapeutics, Inc.			1948100	07/05/2017	These shares were acquired in exchange for Agenus Inc.'s initial capital contribution.

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by INKT disclose?

The filing discloses a proposed sale of 786,750 common shares with an aggregate market value of $12,572,265, to be sold approximately on 08/29/2025 on the INKT exchange.

Who originally acquired the shares being sold according to the Form 144?

The shares were acquired on 07/05/2017 in an original issuance from the issuer when it was a wholly owned subsidiary of Agenus Inc., received in exchange for Agenus Inc.'s initial capital contribution.

Has the filer sold any INKT securities in the past three months?

The filing states Nothing to Report for securities sold during the past three months.

Does the filer assert knowledge of any undisclosed material adverse information?

By signing the notice the person represents they do not know any material adverse information about the issuer that has not been publicly disclosed.

On what date is the sale approximately scheduled?

The approximate date of sale listed is 08/29/2025.